NVCT vs PSA · $304.5M cap vs rev $4.82B
Nuvectis Pharma Inc (NVCT) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Nuvectis Pharma Inc (NVCT) is a biotechnology company listed on NASDAQ.
PSA (PSA) common stock.
NVCT does not have a complete income-statement cache yet.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
NVCT currently screens at market cap $304.5M. PSA currently screens at market cap $0.
Not investment advice. Open the NVCT and PSA stock pages for the full models.
Not investment advice.